Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:HOTH NASDAQ:JAGX NASDAQ:MLND NASDAQ:TNXP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHOTHHoth Therapeutics$0.69+7.8%$0.74$0.49▼$2.12$12.24M0.57836,416 shs397,305 shsJAGXJaguar Animal Health$2.91-16.1%$10.82$2.53▼$171.50$1.08M0.01147,954 shs121,713 shsMLNDMillendo Therapeutics$1.56$4.00$0.92▼$16.95$29.71M0.481.52 million shs152,321 shsTNXPTonix Pharmaceuticals$12.77-8.8%$13.75$11.60▼$69.97$223.17M1.68399,540 shs617,970 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHOTHHoth Therapeutics+7.81%+9.00%-13.54%-34.29%-17.37%JAGXJaguar Animal Health-16.14%-25.77%-79.71%-86.35%-98.05%MLNDMillendo Therapeutics0.00%0.00%0.00%-35.00%-76.72%TNXPTonix Pharmaceuticals-8.79%-18.87%-2.59%-9.05%-54.92%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHOTHHoth Therapeutics$0.69+7.8%$0.74$0.49▼$2.12$12.24M0.57836,416 shs397,305 shsJAGXJaguar Animal Health$2.91-16.1%$10.82$2.53▼$171.50$1.08M0.01147,954 shs121,713 shsMLNDMillendo Therapeutics$1.56$4.00$0.92▼$16.95$29.71M0.481.52 million shs152,321 shsTNXPTonix Pharmaceuticals$12.77-8.8%$13.75$11.60▼$69.97$223.17M1.68399,540 shs617,970 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHOTHHoth Therapeutics+7.81%+9.00%-13.54%-34.29%-17.37%JAGXJaguar Animal Health-16.14%-25.77%-79.71%-86.35%-98.05%MLNDMillendo Therapeutics0.00%0.00%0.00%-35.00%-76.72%TNXPTonix Pharmaceuticals-8.79%-18.87%-2.59%-9.05%-54.92%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceHOTHHoth Therapeutics 2.00Hold$5.00624.64% UpsideJAGXJaguar Animal Health 1.00SellN/AN/AMLNDMillendo Therapeutics 0.00N/AN/AN/ATNXPTonix Pharmaceuticals 2.67Moderate Buy$22.0072.28% UpsideCurrent Analyst Ratings BreakdownLatest JAGX, MLND, HOTH, and TNXP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/5/2026TNXPTonix Pharmaceuticals TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy5/4/2026TNXPTonix Pharmaceuticals TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$22.004/24/2026HOTHHoth Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/21/2026JAGXJaguar Animal Health Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/20/2026TNXPTonix Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/25/2026HOTHHoth Therapeutics D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.003/4/2026HOTHHoth Therapeutics D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.00(Data available from 5/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookHOTHHoth TherapeuticsN/AN/AN/AN/A$0.22 per shareN/AJAGXJaguar Animal Health$11.51M0.09N/AN/A($42.30) per share-0.07MLNDMillendo TherapeuticsN/AN/AN/AN/A$1.78 per shareN/ATNXPTonix Pharmaceuticals$13.11M15.53N/AN/A$14.25 per share0.90Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateHOTHHoth Therapeutics-$12.47M-$0.80N/AN/AN/AN/A-165.25%-143.61%6/3/2026 (Estimated)JAGXJaguar Animal Health-$53.43M-$1,162.24N/AN/AN/A-169.04%-1,194.94%-115.55%N/AMLNDMillendo Therapeutics-$36.41MN/AN/AN/AN/AN/A-91.03%-72.44%N/ATNXPTonix Pharmaceuticals-$124.02M-$14.36N/AN/AN/A-839.52%-67.65%-60.47%8/10/2026 (Estimated)Latest JAGX, MLND, HOTH, and TNXP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/3/2026N/AHOTHHoth Therapeutics-$0.1378N/AN/AN/AN/AN/A5/20/2026Q1 2026JAGXJaguar Animal Health-$149.10-$13.60+$135.50-$13.60$4.21 million$20.27 million5/15/2026Q1 2026HOTHHoth Therapeutics-$0.1378-$0.17-$0.0322-$0.17N/AN/A5/11/2026Q1 2026TNXPTonix Pharmaceuticals-$2.54-$2.93-$0.39-$2.93$6.13 million$6.88 million3/27/2026Q4 2025HOTHHoth Therapeutics-$0.1031-$0.16-$0.0569-$0.16N/AN/A3/12/2026Q4 2025TNXPTonix Pharmaceuticals-$3.16-$3.98-$0.82-$3.98$2.97 million$5.39 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthHOTHHoth TherapeuticsN/AN/AN/AN/AN/AJAGXJaguar Animal HealthN/AN/AN/AN/AN/AMLNDMillendo TherapeuticsN/AN/AN/AN/AN/ATNXPTonix PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioHOTHHoth TherapeuticsN/A3.394.72JAGXJaguar Animal Health4.080.500.29MLNDMillendo TherapeuticsN/A6.396.39TNXPTonix PharmaceuticalsN/A6.996.86Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipHOTHHoth Therapeutics7.08%JAGXJaguar Animal Health12.04%MLNDMillendo TherapeuticsN/ATNXPTonix Pharmaceuticals82.26%Insider OwnershipCompanyInsider OwnershipHOTHHoth Therapeutics6.92%JAGXJaguar Animal Health2.10%MLNDMillendo TherapeuticsN/ATNXPTonix Pharmaceuticals2.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableHOTHHoth Therapeutics419.13 million17.80 millionNot OptionableJAGXJaguar Animal Health50370,000364,000No DataMLNDMillendo Therapeutics1219.04 millionN/ANot OptionableTNXPTonix Pharmaceuticals5015.94 million15.62 millionNot OptionableJAGX, MLND, HOTH, and TNXP HeadlinesRecent News About These CompaniesTNXP: Secures commercial payer coverage for Tonmya® to provide access for ~35 million US patientsMay 22 at 8:12 AM | msn.comTNXP: Secures Commercial Payer Coverage for Tonmya® to Provide Access for ~35 Million U.S. PatientsMay 20 at 6:41 PM | finance.yahoo.comTonix Pharmaceuticals (NASDAQ:TNXP) Shares Pass Above Two Hundred Day Moving Average - What's Next?May 19, 2026 | americanbankingnews.comTonix Pharma advances TNX-4800 Lyme vaccine programMay 15, 2026 | tipranks.comTonix Pharmaceuticals Holding (TNXP) price target decreased by 14.88% to 47.18May 14, 2026 | msn.comTonix Pharmaceuticals to Present Retrospective U.S. Real-World Claims Analysis Characterizing Patients with Fibromyalgia at ISPOR 2026May 14, 2026 | finance.yahoo.comTonix Pharmaceuticals to Present Retrospective U.S. Real-World Claims Analysis Characterizing Patients with Fibromyalgia at ISPOR 2026May 14, 2026 | globenewswire.comTonix Pharmaceuticals to Participate in Two Investor Conferences in MayMay 12, 2026 | finance.yahoo.comTonix Pharmaceuticals to Participate in Two Investor Conferences in MayMay 12, 2026 | markets.businessinsider.comTonix Pharmaceuticals to Participate in Two Investor Conferences in MayMay 12, 2026 | globenewswire.comTonix Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational HighlightsMay 11, 2026 | finance.yahoo.comTonix Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational HighlightsMay 11, 2026 | globenewswire.comTonix Pharma Shareholders Approve Reverse Split and Incentive PlanMay 7, 2026 | tipranks.comTNXP stock climbs 7%: Retail bets on $30M revenue upside from Tonmya dealMay 7, 2026 | msn.comWhy Tonix Pharmaceuticals shares are rallying WednesdayMay 7, 2026 | msn.comTonix rises on commercial payer coverage for pain therapyMay 6, 2026 | seekingalpha.comTonix Pharmaceuticals Secures Commercial Payer Coverage for TONMYA®, Providing Access for ~35 Million U.S. PatientsMay 6, 2026 | finance.yahoo.comTonix Pharmaceuticals Secures Commercial Payer Coverage for TONMYA®, Providing Access for ~35 Million U.S. PatientsMay 6, 2026 | globenewswire.comTonix Pharmaceuticals (NASDAQ:TNXP) Stock Rating Upgraded by TD CowenMay 6, 2026 | marketbeat.comTD Cowen initiates coverage of Tonix Pharmaceuticals Holding (TNXP) with buy recommendationMay 6, 2026 | msn.comTonix Pharmaceuticals (TNXP) to Release Quarterly Earnings on MondayMay 4, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeJAGX, MLND, HOTH, and TNXP Company DescriptionsHoth Therapeutics NASDAQ:HOTH$0.69 +0.05 (+7.81%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$0.67 -0.02 (-3.19%) As of 05/22/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in Phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus, as well as a diagnostic device through a mobile device. The company has license agreements with the George Washington University; Isoprene Pharmaceuticals, Inc.; Virginia Commonwealth University; the North Carolina State University; Chelexa BioSciences, Inc. and the University of Cincinnati; Zylö Therapeutics, Inc.; and Voltron Therapeutics, Inc. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York.Jaguar Animal Health NASDAQ:JAGX$2.91 -0.56 (-16.14%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$3.05 +0.14 (+4.78%) As of 05/22/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. The company's products include Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing NP-300, a second-generation antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.Millendo Therapeutics NASDAQ:MLNDAs of June 25, 2021, Millendo Therapeutics, Inc. was acquired by Tempest Therapeutics Inc., in a reverse merger transaction. Millendo Therapeutics, Inc. operates as a biopharmaceutical company. The company is headquartered in Ann Arbor, Michigan.Tonix Pharmaceuticals NASDAQ:TNXP$12.77 -1.23 (-8.79%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$12.89 +0.12 (+0.95%) As of 05/22/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as rare disease, immunology, and infectious disease product candidates. The company's priority is to submit a New Drug Application (NDA) to the FDA for TNX-102 SL (cyclobenzaprine HCl sublingual tablet), which has completed two positive Phase 3 studies for the management of fibromyalgia. TNX-102 SL is also being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition. Its TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted breakthrough therapy designation by the FDA. The company's rare disease development portfolio comprises TNX-2900, an intranasal potentiated oxytocin for the treatment of Prader-Willi syndrome (PWS). Its immunology portfolio includes TNX-1500, which is a biologic to address organ transplant rejection and autoimmune diseases. The company's infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox. TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases, including TNX-1800 and TNX-1850, in development as a vaccine to protect against COVID-19. Its infectious disease development portfolio also comprises TNX-3900, and TNX-4200 are orally available CD45 antagonists in preclinical development. Tonix Pharmaceuticals Holding Corp. has collaboration agreement with Bilthoven Biologicals to advance TNX-801 mpox vaccine candidate; and with X-Chem, Inc. to develop broad-spectrum antivirals. The company was founded in 2007 and is headquartered in Chatham, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/18 - 05/22 SpaceX IPO: Opportunity? Or the Ultimate Hype Trade? Overextended, e.l.f. Beauty Is Primed to Rebound in Back Half Deere Beats Q2 Estimates, But Ag Weakness Weighs on Outlook NVIDIA Price Pullback? Don’t Count on It, Business Is Accelerating Meta Platforms 10% Layoff Raises a Bigger Question About AI Spending Intuit's Great SaaS Reset: Fired By AI Biogen Stock Slides After Trial Miss, But Analysts Stay Bullish Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
